Evidence map›Paper›PMID 38982828›Full record

Trial reportThe American journal of psychiatry2024

Entactogen Effects of Ketamine: A Reverse-Translational Study.

Evan M Hess, Dede K Greenstein, Olivia L Hutchinson, Carlos A Zarate, Todd D Gould

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The psychedelic-peptide paradox: a hormetic hypothesis.Comprehensive psychoneuroendocrinology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Evan M HessDepartment of Psychiatry (Hess, Hutchinson, Gould), Department of Neurobiology (Gould), and Department of Pharmacology (Gould), University of Maryland School of Medicine, Baltimore; Experimental Therapeutics and Pathophysiology Branch, NIMH, Bethesda, Md. (Greenstein, Zarate); Baltimore Veterans Affairs Medical Center, Veterans Affairs Maryland Health Care System, Baltimore (Gould).
Dede K GreensteinDepartment of Psychiatry (Hess, Hutchinson, Gould), Department of Neurobiology (Gould), and Department of Pharmacology (Gould), University of Maryland School of Medicine, Baltimore; Experimental Therapeutics and Pathophysiology Branch, NIMH, Bethesda, Md. (Greenstein, Zarate); Baltimore Veterans Affairs Medical Center, Veterans Affairs Maryland Health Care System, Baltimore (Gould).
Olivia L HutchinsonDepartment of Psychiatry (Hess, Hutchinson, Gould), Department of Neurobiology (Gould), and Department of Pharmacology (Gould), University of Maryland School of Medicine, Baltimore; Experimental Therapeutics and Pathophysiology Branch, NIMH, Bethesda, Md. (Greenstein, Zarate); Baltimore Veterans Affairs Medical Center, Veterans Affairs Maryland Health Care System, Baltimore (Gould).
Carlos A ZarateDepartment of Psychiatry (Hess, Hutchinson, Gould), Department of Neurobiology (Gould), and Department of Pharmacology (Gould), University of Maryland School of Medicine, Baltimore; Experimental Therapeutics and Pathophysiology Branch, NIMH, Bethesda, Md. (Greenstein, Zarate); Baltimore Veterans Affairs Medical Center, Veterans Affairs Maryland Health Care System, Baltimore (Gould).
Todd D GouldDepartment of Psychiatry (Hess, Hutchinson, Gould), Department of Neurobiology (Gould), and Department of Pharmacology (Gould), University of Maryland School of Medicine, Baltimore; Experimental Therapeutics and Pathophysiology Branch, NIMH, Bethesda, Md. (Greenstein, Zarate); Baltimore Veterans Affairs Medical Center, Veterans Affairs Maryland Health Care System, Baltimore (Gould).

Funding

Target validation of novel therapeutic agents in mood disordersZIAMH002927 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2010 to 2025
$37.1M
Therapeutic Efficacy of Ketamine Metabolites for Depression TreatmentR01MH107615 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOULD, TODD D · 2016 to 2025
$7.2M
Multidisciplinary Schizophrenia Research TrainingT32MH067533 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI CARPENTER, WILLIAM T., ELMER, GREGORY I · 2004 to 2025
$4.3M
Hydroxynorketamine for the Treatment of PTSD and AnhedoniaI01BX004062 · VA · BALTIMORE VA MEDICAL CENTER · PI GOULD, TODD D · 2019 to 2023
–
Estradiol treatment of stress-related psychiatric disorders in VeteransI01BX006018 · VA · BALTIMORE VA MEDICAL CENTER · PI Todd D Gould · 2023 to 2026
–
BLRD VA I01 BX004062BLRD VA I01 BX006018Intramural NIH HHS ZIA MH002927NIMH NIH HHS L30 MH091729NIMH NIH HHS R01 MH107615NIMH NIH HHS T32 MH067533
6 · The paper itself

Abstract

objectiveThe authors sought to assess the prosocial, entactogen effects of ketamine.

methodsPleasure from social situations was assessed in a sample of participants with treatment-resistant depression from randomized, double-blind, placebo-controlled studies, using four items of the Snaith-Hamilton Pleasure Scale (SHAPS) at five time points over 1 week following treatment with ketamine (0.5 mg/kg intravenously) or placebo. The primary endpoint was postinfusion self-reported pleasure on the four SHAPS items pertaining to social situations, including the item on helping others, between the ketamine and placebo groups. In a rodent experiment, the impact of ketamine on helping behavior in rats was assessed using the harm aversion task. The primary endpoint was a reduction in lever response rate relative to baseline, which indicated the willingness of rats to forgo obtaining sucrose to help protect their cage mate from electric shock.

resultsRelative to placebo, ketamine increased ratings of feeling pleasure from being with family or close friends, seeing other people's smiling faces, helping others, and receiving praise, for 1 week following treatment. In the rodent experiment, during the harm aversion task, ketamine-treated rats maintained lower response rates relative to baseline to a greater extent than what was observed in vehicle-treated rats for 6 days posttreatment and delivered fewer shocks overall.

conclusionsIn patients with treatment-resistant depression, ketamine treatment was associated with increased pleasure from social situations, such as feeling pleasure from helping others. Ketamine-treated rats were more likely to protect their cage mate from harm, at the cost of obtaining sucrose. These findings suggest that ketamine has entactogen effects.

Indexed as

Depressive Disorder, Treatment-ResistantKetamineAdultAnimalsCross-Over StudiesDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleHumansMaleMiddle AgedPleasureRatsSocial BehaviorExcitatory Amino Acid AntagonistsKetamineAntidepressantsDepressive DisordersEntactogensKetamine/Esketamine

Identifiers

PMID38982828
PMCPMC11492270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.